A single dose of MRT5005, Translate Bio‘s first-in-class messenger RNA (mRNA) therapy for the treatment of…
Joana Carvalho, PhD
Joana holds a bachelor’s in biology, a Master of Science in evolutionary and developmental biology, and a PhD in biomedical sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Joana Carvalho, PhD
The European Commission (EC) and the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) granted Mylan the right to…
NIH $150,000 Grant to Support Research into Preserving Fertility in Women Prior to Lung Transplant
Sigrid Ladores, PhD, an associate professor at the University of Alabama at Birmingham School of Nursing, was awarded a…
Oleh Taratula, PhD, a researcher at Oregon State University‘s College of Pharmacy, has been awarded a $2.3 million five-year grant…
Eluforsen, an investigational therapy for the treatment of cystic fibrosis (CF), improves the function of the cystic fibrosis…
People with cystic fibrosis (CF) may require a modified and more rigorous cleansing procedure to prepare their bowels for…
The U.S. Food and Drug Administration (FDA) has approved Symdeko (tezacaftor/ivacaftor and ivacaftor) tablets for the…
Small proteins with antimicrobial properties found in the mucus of the brown garden snail may open the door to the…
EffRx Pharmaceuticals announced that it has signed an exclusive license agreement with Pharmaxis to register and commercialize Bronchitol…
Murepavadin (POL7080), Polyphor‘s lead investigational antibiotic targeting Gram-negative bacteria, behaved as expected and was well-tolerated when administered…